Toxic neuropathies: Mechanistic insights based on a chemical perspective

Neuroscience Letters

Volumn 596, Issue , 2015, Pages 78-83

  LoPachin, Richard M ^a   Gavin, Terrence ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b IONA COLLEGE   (United States)

Author keywords

2,5 Hexanedione; Acrylamide; Central peripheral distal axonopathy; Dying back neuropathy; Neurotoxicity; Peripheral neuropathy

Indexed keywords

1,4 DIKETONE; 2 HEXANONE; ACETONYLACETONE; ACRYLAMIDE; CYTOSKELETON PROTEIN; HEXANE; LYSINE; 2,5-HEXANEDIONE; ALKANONE; POLLUTANT;

NERVE FIBER DEGENERATION; NEUROPATHY; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SHORT SURVEY; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICALLY INDUCED; DRUG EFFECTS; HUMAN; NERVE FIBER; PATHOLOGY; POLLUTANT; TOXICITY;

AXONS; CENTRAL NERVOUS SYSTEM DISEASES; ENVIRONMENTAL POLLUTANTS; HEXANONES; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84929659660     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.08.054     Document Type: Review

References (42)

1. Spencer P.S., Schaumburg H.H. Classification of neurotoxic disease: a morphological approach. Experimental and Clinical Neurotoxicology 1980, 92-99. Williams & Wilkins, Baltimore, MD. P.S. Spencer, H.H. Schaumburg (Eds.).
2. LoPachin R.M., Gavin T. Molecular mechanism of acrylamide neurotoxicity: lessons learned from organic chemistry. Environ. Health Perspect. 2012, 120:1650-1657.
3. LoPachin R.M., Lehning E.J. Acrylamide-induced distal axon degeneration: a proposed mechanism of action. NeuroToxicology 1994, 15:247-260.
4. LoPachin R.M., DeCaprio A.P. γ-Diketone neuropathy: axon atrophy and the role of cytoskeletal protein adduction. Toxicol. Appl. Pharmacol. 2004, 199:20-34.
5. LoPachin R.M., Lehning E.J. The relevance of axonal swelling and atrophy to γ-diketone neurotoxicity. NeuroToxicology 1997, 18:7-22.
6. LoPachin R.M., Balaban C.D., Ross J.F. Acrylamide axonopathy revisited. Toxicol. Appl. Pharmacol. 2003, 188:135-153.
7. Crofton K.M., Padilla S., Tilson H.A., Anthony D.C., Raymer J.H., MacPhail R.C. The impact of dose-rate on the neurotoxicity of acrylamide: the interaction of administered dose, target tissue concentration, tissue damage and functional effects. Toxicol. Appl. Pharmacol. 1996, 139:163-176.
8. Lehning E.J., Persaud A., Dyer K.S., Jortner B.S., LoPachin R.M. Biochemical and morphological characterization of acrylamide peripheral neuropathy. Toxicol. Appl. Pharmacol. 1998, 151:211-221.
9. Graham D.G., Amarnath V., Valentine W.M., Pyle S.J., Anthony D.C. Pathogenic studies of hexane and carbon disulfide neurotoxicity. Crit. Rev. Toxicol. 1995, 25:91-112.
10. LoPachin R.M., DeCaprio A.P. Protein adduct formation as a molecular mechanism in neurotoxicity. Toxicol. Sci. 2005, 86:214-225.
11. Monaco S., Simonati A., Rizzuto N., Autilio-Gambetti L., Gambetti P. Hexacarbon axonopathy: the morphological expression of altered cytoskeletal translocation. Neurodegenerative Disorders: The Role Played by Endotoxin and Xenobiotics 1988, Raven Press, New York. G. Nappi (Ed.).
12. LoPachin R.M., Lehning E.J., Stack E.C., Hussein S.J., Saubermann A.J. 2,5-Hexanedione alters elemental composition and water content of rat peripheral nerve myelinated axons. J. Neurochem. 1994, 63:2266-2278.
13. LoPachin R.M., Jortner B.S., Reid M., Das S. γ-Diketone central neuropathy: quantitative morphometric analysis of axons in rat spinal cord white matter regions and nerve roots. Toxicol. Appl. Pharmacol. 2003, 193:29-46.
14. LoPachin R.M., Jortner B.S., Reid M., Monir A. γ-Diketone central neuropathy: quantitative analyses of cytoskeletal components in myelinated axons of rat rubrospinal tract. NeuroToxicology 2005, 26:1021-1030.
15. Lehning E.J., Dyer K.S., Jortner B.S., LoPachin R.M. Axon atrophy is a specific component of 2,5-hexanedione peripheral neuropathy. Toxicol. Appl. Pharmacol. 1995, 135:58-66.
16. Lehning E.J., Jortner B.S., Fox J.H., Arezzo J.C., Kitano T., LoPachin R.M. γ-Diketone peripheral neuropathy. 1. Quantitative morphometric analyses of axonal atrophy and swelling. Toxicol. Appl. Pharmacol. 2000, 165:127-140.
17. Chiu F.C., Opanashuk L.A., He D.K., Lehning E.J., LoPachin R.M. γ-Diketone peripheral neuropathy. II. Neurofilament subunit content. Toxicol. Appl. Pharmacol. 2000, 165:141-147.
18. DeCaprio A.P., O'Neill E.A. Alterations in rat axonal cytoskeletal proteins induced by in vitro and in vivo 2,5-hexanedione exposure. Toxicol. Appl. Pharmacol. 1985, 78:235-247.
19. LoPachin R.M., He D., Reid M.L. 2,5-Hexanedione-induced changes in the neurofilament subunit pools of rat peripheral nerve. NeuroToxicology 2005, 198:229-240.
20. Opanashuk L.A., He D., Lehning E.J., LoPachin R.M. γ-Diketone peripheral neuropathy. III. Neurofilament gene expression. NeuroToxicology 2001, 22:215-220.
21. Sickles D.W. Toxic neurofilamentous axonopathies and fast anterograde axonal transport. I. The effects of single doses of acrylamide on the rate and capacity of transport. NeuroToxicology 1989, 10:91-102.
22. LoPachin R.M., He D., Reid M.L., Opanashuk L.A. 2,5-Hexanedione-induced changes in the monomeric neurofilament protein content of rat spinal cord fractions. Toxicol. Appl. Pharmacol. 2004, 198:61-73.
23. Yabe J.T., Jung C., Chan W.K., Shea T.B. Phospho-dependent association of neurofilament proteins with kinesin in situ. Cell Motil. Cytoskeleton 2000, 45:249-262.
24. DeCaprio A.P., Fowke J.H. Limited and selective adduction of carboxyl-terminal lysines in the high molecular weight neurofilament proteins by 2,5-hexanedione in vitro. Brain Res. 1992, 586:219-228.
25. DeCaprio A.P., Kinney E.A., Fowke J.H. Regioselective binding of 2,5-hexanedione to high-molecular-weight rat neurofilament proteins in vitro. Toxicol. Appl. Pharmacol. 1997, 145:211-217.
26. Ackerley S., Thornhill P., Grierson A.J., Brownlees J., Anerton B.H., Leigyh P.N., Shaw C.E., Miller C.C.J. Neurofilament heavy chain side arm phosphorylation regulates axonal transport of neurofilaments. J. Cell Biol. 2003, 161:489-495.
27. Zhang L., Gavin T., DeCaprio A.P., LoPachin R.M. γ-Diketone axonopathy: analyses of cytoskeletal motors and highways in CNS myelinated axons. Toxicol. Sci. 2010, 117:180-189.
28. Lorand L., Graham R.M. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell Biol. 2003, 4:140-156.
29. Sickles D.W., Pearson J.K., Beall A., Testino A. Toxic axonal degeneration occurs independent of neurofilament accumulation. J. Neurosci. Res. 1994, 39:347-354.
30. Okada Y., Hirokawa N. Mechanism of the single-headed processivity: diffusional anchoring between the K-loop of kinesin and the C terminus of tubulin. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:640-645.
31. Iwabata J., Yoshida M., Komatsu Y. Proteomic analysis of organ-specific post-translational lysine-acetylation and -methylation in mice by use of anti-acetyllysine and -methyllysine mouse monoclonal antibodies. Proteomics 2005, 5:4653-4664.
32. Hirokawa N. Microtubule organization and dynamics dependent on microtubule-associated proteins. Curr. Opin. Cell Biol. 1994, 6:74-81.
33. Edlemann W., Zervas M., Costello P., Roback L., Fischer I., Hammarback J.A., Cowan N., Davies P., Wainer B., Kucherlapati R. Neuronal abnormalities in microtubule-associated protein 1B mutant mice. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:1270-1275.
34. Tshala-IKatumbay D., Monterroso V., Kayton R., Lasarev M., Sabri M., Spencer P. Probing mechanism of axonopathy. Part II. Protein targets of 2,5-hexanedione, the neurotoxic metabolite of the aliphatic solvent n-hexane. Toxicol. Sci. 2009, 107:482-489.
35. LoPachin R.M., Gavin T., DeCaprio A., Barber D.S. Application of the hard and soft, acids and bases (HSAB) theory to toxicant-target interactions. Chem. Res. Toxicol. 2012, 25:239-251.
36. DeCaprio A.P., Jackowski S.J., Regan K.A. Mechanism of formation and quantitation of imines, pyrroles, and stable nonpyrrole adducts in 2,5-heanedione-treated protein. Mol. Pharmacol. 1987, 32:542-548.
37. DeCaprio A.P., Olajos E.J., Weber P. Covalent binding of a neurotoxic n-hexane metabolite: conversion of primary amines to substituted pyrrole adducts by 2,5-hexanedione. Toxicol. Appl. Pharmacol. 1982, 65:440-450.
38. DeCaprio A.P., Briggs R.G., Jackowski J.J., Kim J.C.S. Comparative neurotoxicity and pyrrole-forming potential of 2,5-hexanedione and perdeuterio-2,5-hexanedione in the rat. Toxicol. Appl. Pharmacol. 1988, 92:75-85.
39. Genter M.B., Szakal-Quin G., Anderson C.W., Anthony D.C., Graham D.G. Evidence that pyrrole formation is a pathogenic step in γ-diketone neuropathy. Toxicol. Appl. Pharmacol. 1987, 87:351-362.
40. a lysine residues at the active site of sarcosine oxidase from Corynebacterium sp. U-96. Biochem. Biophys. Commun. 2004, 320:846-851.
41. Boekelheide K., Fleming S.L., Allio T., Embree-Ku M.E., Hall S.J., Johnson K.J., Kwon E.J., Patel S.R., Rasoulpour R.J., Schoenfeld H.A., Thompson S. 2,5-Hexanedione-induced testicular injury. Annu. Rev. Pharmacol. Toxicol. 2003, 43:125-147.
42. DeCaprio A.P. Molecular mechanisms of diketone neurotoxicity. Chem. Biol. Interact. 1985, 54:257-270.